Twenty years ago, the Human Genome Project was completed. It unveiled a mostly complete sequence of the 3 billion pairs of building blocks that make up the code within every set of human chromosomes. These are the instructions that create humans. Almost all of human biology research uses the Human Genome Project’s findings in some way, from understanding why some people are more likely to develop diseases than others, to uncovering the secrets of our ancestors and evolution. But for genomics to become a part of everyday medicine, paving the way for personalised medicines, the hard work is still ahead.

Natasha Loder, The Economist’s health editor and Geoff Carr, our senior editor for science and technology, reflect on the completion of the Human Genome Project in the early 2000s and the gaps that still remain. Natasha also visits the Wellcome Sanger Institute, to explore the next frontiers for genomics in medicine—she meets the outgoing director, Mike Stratton; the incoming director, Matt Hurles; and the boss of the European Bioinformatics Institute, Ewan Birney. Plus, Mathew Davies, an engineer at the Sanger Institute, and his team, discuss the challenges with storing and processing vast amounts of sequencing data. Alok Jha, The Economist’s science and technology editor, hosts.

To dive deeper on genomics, find our recent episode from the Third International Summit on Human Genome Editing, or explore the power of gene therapies, and also an explainer on how genomic sequencing works.

If you love Babbage, why not work with us? We’re hiring for an Assistant Audio Producer to work on the show. Apply by May 15th.

For full access to The Economist’s print, digital and audio editions subscribe at economist.com/podcastoffer and sign up for our weekly science newsletter at economist.com/simplyscience.

Hosted on Acast. See acast.com/privacy for more information.

This week, the European Space Agency is expected to launch a spacecraft towards Jupiter and three of its icy moons—Ganymede, Europa and Callisto. The JUICE mission will carry ten instruments to the outer solar system and will hunt for water, a heat source and organic material—the ingredients that scientists think are needed for life. It is hoped the results that come from JUICE, and a similar NASA mission, Europa Clipper, will give us scientists a clearer view of whether life exists beyond planet Earth. 

Tim Cross, The Economist’s deputy science editor, explains why missions to the Jovian system represent a shift away from Mars, to hunt for extraterrestrial life. Plus, Jason Hosken, our producer, visits Imperial College London to find out how the JUICE magnetometer works, with engineers Patrick Brown and Richard Baughen. He also asks Michele Dougherty, the instrument’s principal investigator, about the mission’s scientific aims. Alok Jha, The Economist’s science and technology editor, hosts.

This is the second episode on the grand scientific quest to search for life beyond Earth. Last week, we asked exoplanet hunter and Nobel laureate, Didier Queloz, how to start answering one of the universe’s most intriguing questions. Listen at economist.com/queloz-pod or on your podcast app.

For full access to The Economist’s print, digital and audio editions subscribe at economist.com/podcastoffer and sign up for our weekly science newsletter at economist.com/simplyscience.

Hosted on Acast. See acast.com/privacy for more information.

As they stare up into the night sky, astronomers have long wondered whether life exists elsewhere in the universe. For decades, the hunt for extraterrestrial life has focused on Mars, Venus and even on the various moons of our solar system. But in 1995, that search entered a new phase, when Didier Queloz and Michel Mayor found the first clear evidence of a planet orbiting another star: 51 Pegasi b. Since then, more than 5,000 exoplanets have been found. This week, Alok Jha asks Nobel laureate Dider Queloz, how the “exoplanet revolution” has influenced the search for life elsewhere.

Dider Queloz is the founding director of the Center for the Origin and Prevalence of Life at ETH Zurich and the director of the Leverhulme Centre for Life in the Universe at the University of Cambridge. We also hear from Emily Mitchell, the co-director of the Leverhulme Centre, on what an international collaboration of scientists called the “Origins Federation” has set out to study. Alok Jha, The Economist’s science and technology editor, hosts.

This is the first of two episodes on the grand scientific quest to search for life beyond Earth. Next time, we’ll explore the European Space Agency’s mission to Jupiter’s icy moons: JUICE.

For full access to The Economist’s print, digital and audio editions subscribe at economist.com/podcastoffer and sign up for our weekly science newsletter at economist.com/simplyscience.

Hosted on Acast. See acast.com/privacy for more information.

Imagine a power source that produces hardly any waste and is carbon-free. That’s the tantalising promise of controlled nuclear fusion, which physicists have been trying to achieve for 70 years. It is a simulacrum of the process that powers the sun, colliding atomic nuclei of various sorts to release huge amounts of energy. 

Fusion research was once the provenance of governments and national laboratories, but now private companies are getting in on the act. Dozens of them are exploring different ways to create the extreme conditions needed to achieve fusion here on Earth. And, contrary to the old joke that fusion power is thirty years away, and always will be, some of them think they can get there in a decade.

Fernanda Rimini, an experimental fusion scientist with the UK Atomic Energy Authority, explains how nuclear fusion works. Geoff Carr, The Economist’s science and technology editor, explores why fusion is coming back into fashion for private companies. Geoff also speaks to Bob Mumgaard of Commonwealth Fusion Systems, Warrick Matthews of Tokamak Energy and Nick Hawker of First Light Fusion. Plus, Stephen Cowley, the director of the Princeton Plasma Physics Laboratory assesses how helpful the latest private fusion ventures are in advancing the field. Alok Jha hosts.

Hosted on Acast. See acast.com/privacy for more information.

OpenAI's ChatGPT, an advanced chatbot, has taken the world by storm, amassing over 100 million monthly active users and exhibiting unprecedented capabilities. From crafting essays and fiction to designing websites and writing code, you’d be forgiven for thinking there’s little it can’t do. 

Now it’s had an upgrade. GPT-4 has even more incredible abilities, it can take in photos as an input, and deliver smoother, more natural writing to the user. But it also hallucinates, throws up false answers, and remains unable to reference any world events that happened after September 2021.

Seeking to get under the hood of the Large Language Model that operates GPT-4, host Alok Jha speaks with Maria Laikata, a professor in Natural Language Processing at Queen Mary University of London. We put the technology through its paces with The Economist’s tech-guru Ludwig Seigele, and even run it through something like a Turing Test to give an idea of whether it could pass for human-level-intelligence. 

An Artificial General Intelligence is the ultimate goal of AI research, so how significant will GPT-4 and similar technologies be in the grand scheme of machine intelligence? Not very, suggests Gary Marcus, expert in both AI and human intelligence, though they will impact all of our lives both in good and bad ways. 

For full access to The Economist’s print, digital and audio editions subscribe at economist.com/podcastoffer and sign up for our weekly science newsletter at economist.com/simplyscience.

Hosted on Acast. See acast.com/privacy for more information.

A new class of drugs for weight loss have become available and are showing promising results. That’s welcome news, as a recent report estimates that half of the world’s population is expected to be overweight or obese by 2035. Obesity is a disease which can lead to serious health complications–and most previous attempts at treating it have proven futile. Can the new weight-loss drugs turn the tide against this global threat?

Louise Baur, president of the World Obesity Federation crunches the numbers on the global impact of overweight and obesity. Stephan Guyenet, a neurobiologist and author of “The Hungry Brain”, explains the neurological and genetic factors that influence weight gain. Chris van Tulleken, an infectious diseases doctor at University College London and author of the upcoming book “Ultra-Processed People”, explores how the modern diet is contributing to the obesity epidemic–and other health problems. Plus, host Alok Jha asks Natasha Loder, The Economist’s health editor, how important the new skinny jabs are in the fight against obesity.

For full access to The Economist’s print, digital and audio editions subscribe at economist.com/podcastoffer and sign up for our weekly science newsletter at economist.com/simplyscience.

Hosted on Acast. See acast.com/privacy for more information.

The Third International Summit on Human Genome Editing was held this week in London. It was the first such meeting since 2018, when a Chinese researcher announced that he had created the world’s first genetically edited babies—a move that was roundly condemned at the time. Host Alok Jha and Natasha Loder, The Economist’s health editor, report from the conference to explore the exciting future—and knotty challenges—of the world that gene-editing therapies could create.

Robin Lovell-Badge, a leading scientist at the Francis Crick Institute in London and the organiser of the summit, explains how genome-editing technology has rapidly advanced in recent years. Claire Booth, a professor of gene therapy and paediatric immunology at Great Ormond Street Hospital and University College London discusses the hopes of gene-editing treatments. Plus, Kelly Ormond, a bioethicist from ETH-Zurich, explores the ethical dilemmas that are raised by the technology, and Filippa Lentzos of King’s College London, explains why human genome editing presents potential biosecurity risks.

Listen to previous episodes of “Babbage” on the topic: the gene therapy revolution and an interview with Jennifer Doudna, the pioneer of CRISPR-Cas9 technology. 

For full access to The Economist’s print, digital and audio editions subscribe at economist.com/podcastoffer and sign up for our weekly science newsletter at economist.com/simplyscience.

Hosted on Acast. See acast.com/privacy for more information.

There is a worrying amount of fraud in medical research. As many as one in 50 research papers may be unreliable because of fabrication, plagiarism or serious errors. Fabricated data can influence the guidelines which doctors use to treat patients. Misguided clinical guidelines could cause serious illness and death in patients. Fraudulent studies can also influence further research programmes—recent findings suggest that manipulated images may have resulted in scientists wasting time and money following blind alleys in Alzheimer’s research for decades. What can be done to combat scientific malpractice? 

Dorothy Bishop, a retired professor of psychology at the University of Oxford, explores the motivation behind fraudsters in research. John Carlisle, an anaesthetist and an editor of the journal Anaesthesia, explains the impact of fraud and how to detect it in research papers. Also, Elisabeth Bik, a former microbiologist and a full-time scientific image detective, discusses the consequences of whistle-blowing on both sleuths and the fraudsters. Plus, The Economist’s health-care correspondent, Slavea Chankova, investigates how to overcome the worrying unwillingness on all sides to do anything about fraud in research. Alok Jha hosts.

For full access to The Economist’s print, digital and audio editions subscribe at economist.com/podcastoffer and sign up for our weekly science newsletter at economist.com/simplyscience.

Hosted on Acast. See acast.com/privacy for more information.

Over the past few years, hundreds of rugby players have launched class-action lawsuits against the sport’s governing bodies, accusing them of failing to do enough to protect players from head injuries. They say that repeated blows to the head, sustained through years of playing rugby, or other sports, have caused neurodegenerative conditions like dementia, motor neurone and Parkinson’s diseases. But can scientific evidence prove a link between contact sports and these brain conditions? 

Alix Popham, a Welsh former professional rugby player, tells his story of head injuries on the pitch and his desired outcomes from the lawsuits. Plus, Lauren Pulling, who runs the Drake Foundation, explains the current state of neuroscientific research and what further studies are needed to investigate the connection. Alok Jha hosts with Natasha Loder, The Economist’s health editor, and Georgia Banjo, our Britain correspondent. 

For full access to The Economist’s print, digital and audio editions subscribe at economist.com/podcastoffer and sign up for our weekly science newsletter at economist.com/simplyscience.

Hosted on Acast. See acast.com/privacy for more information.

Over the past 18 months, the largest-ever recorded avian influenza outbreak has decimated bird populations around the world. But recently bird flu has spread to mammals. Last week, Peru reported the deaths of 585 sea lions. If the virus has mutated to enable mammal-to-mammal transmission, that could be an intermediate step towards human-to-human transmission. How worrying is this threat?

Susan Davies, CEO of the Scottish Seabird Centre, describes how the H5N1 avian flu has affected populations of wild birds. Ian Brown of Britain’s Animal and Plant Health Agency explains why the dynamics of this outbreak are concerning scientists. Plus, we ask Marion Koopmans, head of viroscience at Erasmus MC, why she’s more worried than ever about a human influenza pandemic. The Economist’s Slavea Chankova also compares the influenza threat to the covid-19 pandemic. Do we have enough tools in our arsenal? Alok Jha hosts. 

For full access to The Economist’s print, digital and audio editions subscribe at economist.com/podcastoffer and sign up for our weekly science newsletter at economist.com/simplyscience.

Hosted on Acast. See acast.com/privacy for more information.